<p>Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, has announced a partnership with DoctorBox, one of Germany’s leading digital health platforms. Through this collaboration, Mainz Biomed’s DNA-based colorectal cancer screening test, ColoAlert®, will be added to DoctorBox’s portfolio of preventive healthcare services. The partnership aims to expand access to at-home colorectal cancer screening, with laboratory analysis provided by the European Oncology Lab. This move supports Mainz Biomed’s European growth strategy and highlights the increasing role of digital solutions in preventive medicine. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001142143-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

MYNZ

<p>Mainz Biomed NV has partnered with DoctorBox to offer ColoAlert®, a home DNA colorectal cancer test, expanding access to at-home screening in Europe. This collaboration supports Mainz Biomed's growth strategy and emphasizes the role of digital solutions in preventive medicine.</p>

Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test